New AI platform detects neurodegenerative diseases in brain tissue samples

Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative disease in human brain tissue samples, including Alzheimer's disease and chronic traumatic encephalopathy, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published in the Nature medical journal Laboratory Investigation. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases that improve patient outcomes.

The buildup of abnormal tau proteins in the brain in neurofibrillary tangles is a feature of Alzheimer's disease, but it also accumulates in other neurodegenerative diseases, such as chronic traumatic encephalopathy and additional age-related conditions. Accurate diagnosis of neurodegenerative diseases is challenging and requires a highly-trained specialist.

Researchers at the Center for Computational and Systems Pathology at Mount Sinai developed and used the Precise Informatics Platform to apply powerful machine learning approaches to digitized microscopic slides prepared using tissue samples from patients with a spectrum of neurodegenerative diseases. Applying deep learning, these images were used to create a convolutional neural network capable of identifying neurofibrillary tangles with a high degree of accuracy directly from digitized images.

"Utilizing artificial intelligence has great potential to improve our ability to detect and quantify neurodegenerative diseases, representing a major advance over existing labor-intensive and poorly reproducible approaches," said lead investigator John Crary, MD, PhD, Professor of Pathology and Neuroscience at the Icahn School of Medicine at Mount Sinai. "Ultimately, this project will lead to more efficient and accurate diagnosis of neurodegenerative diseases."

This is the first framework available for evaluating deep learning algorithms using large-scale image data in neuropathology. The Precise Informatics Platform allows for data managements, visual exploration, object outlining, multi-user review, and evaluation of deep learning algorithm results.

Researchers at the Center for Computational and Systems Pathology at Mount Sinai have used use advanced computer science and mathematical techniques coupled with cutting-edge microscope technology, computer vision, and artificial intelligence to more accurately classify a broad array of diseases.

"Mount Sinai is the largest academic pathology department in the country and processes more than 80 million tests a year, which offers researchers access to a broad set of data that can be used to improve testing and diagnostics, ultimately leading to better diagnosis and patient outcomes," said author Carlos Cordon-Cardo, MD, PhD, Chair of the Department of Pathology at the Mount Sinai Health System and Professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring AI’s impact on precision oncology